September 5, 2014 — Telemis announced another record year of trading with revenues increasing by more than 6 percent. Now in its 12th consecutive year of profitability, the latest results reflect the success of the ongoing Telemis strategy to invest heavily in R&D for the delivery of advanced MACS (Multimedia Archive and Communication Systems) solutions that support early and precise diagnosis of cancer, heart disease and other critical pathologies.
Audited accounts for the year to March 31, 2014 show that Telemis annual revenues rose from €7,839,853 to €8,345,023 with a net profit of €665,338. The company’s increasingly healthy financial position is also reflected in a total equity of €6,058,630 on a balance sheet of €14,248,711, while cash at hand stands at €2,647,016.
Telemis attributes its ongoing growth to the evolution of its MACS strategy, which is designed to provide solutions that allow healthcare professionals to quickly and easily record, store, retrieve and share all types of imaging materials including non radiology content. This strategy has been developed in close conjunction with users, including the feedback received during regular Telemis user group meetings. Significant investment in R&D is a continuing theme, leading to new and more powerful tools such as the latest version of Telemis PACS (version 4.5), which was launched at last year’s Journées Françaises de Radiologie (JFR) technical exhibition and congress.
Announcing the results at the annual shareholder meeting, Telemis Group CEO Stephane Ketelaer, stated: “Twelve years of consecutive profitability and continued revenue growth is testimony to our strategy of listening carefully to healthcare professionals and responding through high levels of targeted R&D investment. This results in high levels of customer satisfaction thanks to industry-leading products, technologies and services that provide clinicians with solutions that help them deliver the best possible care to patients. Precise and early diagnosis of cancer, heart disease and other pathologies is critical to desirable outcomes and at Telemis we are completely focused on using our knowledge and expertise to make a positive impact.”
He added: “We anticipate new MACS implementations being rolled out in Europe this year and that there will be further new business opportunities for Telemis solutions in a number of territories as users look to migrate from older or less effective alternatives.”
For more information: www.telemis.com
July 25, 2024 
